The identification of the ADRB3-S100B signaling axis provides a mechanistic framework for understanding SCN-driven BAT regulation and opens new avenues for therapeutic strategies targeting metabolic disorders associated with circadian disruption, such as obesity and insulin resistance. Here, S100B is linked to Other metabolic disease.